22nd Century Income from Continuous Operations 2011-2024 | XXII
22nd Century income from continuous operations from 2011 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
22nd Century Annual Income from Continuous Operations
(Millions of US $) |
| 2023 |
$-55 |
| 2022 |
$-37 |
| 2021 |
$-33 |
| 2020 |
$-20 |
| 2019 |
$-27 |
| 2018 |
$-8 |
| 2017 |
$-13 |
| 2016 |
$-12 |
| 2015 |
$-11 |
| 2014 |
$-16 |
| 2013 |
$-26 |
| 2012 |
$-7 |
| 2011 |
$-1 |
| 2010 |
$-1 |
22nd Century Quarterly Income from Continuous Operations
(Millions of US $) |
| 2024-09-30 |
$-4 |
| 2024-06-30 |
$-2 |
| 2024-03-31 |
$-5 |
| 2023-12-31 |
$-22 |
| 2023-09-30 |
$-8 |
| 2023-06-30 |
$-14 |
| 2023-03-31 |
$-11 |
| 2022-12-31 |
$-3 |
| 2022-09-30 |
$-13 |
| 2022-06-30 |
$-11 |
| 2022-03-31 |
$-9 |
| 2021-12-31 |
$-14 |
| 2021-09-30 |
$-9 |
| 2021-06-30 |
$-4 |
| 2021-03-31 |
$-5 |
| 2020-12-31 |
$-6 |
| 2020-09-30 |
$-4 |
| 2020-06-30 |
$-5 |
| 2020-03-31 |
$-4 |
| 2019-12-31 |
$-6 |
| 2019-09-30 |
$-10 |
| 2019-06-30 |
$-8 |
| 2019-03-31 |
$-2 |
| 2018-12-31 |
$-9 |
| 2018-09-30 |
$6 |
| 2018-06-30 |
$-7 |
| 2018-03-31 |
$1 |
| 2017-12-31 |
$-4 |
| 2017-09-30 |
$-3 |
| 2017-06-30 |
$-3 |
| 2017-03-31 |
$-3 |
| 2016-12-31 |
$-3 |
| 2016-09-30 |
$-3 |
| 2016-06-30 |
$-3 |
| 2016-03-31 |
$-3 |
| 2015-12-31 |
$-3 |
| 2015-09-30 |
$-3 |
| 2015-06-30 |
$-1 |
| 2015-03-31 |
$-4 |
| 2014-12-31 |
$-6 |
| 2014-09-30 |
$-3 |
| 2014-06-30 |
$-2 |
| 2014-03-31 |
$-5 |
| 2013-12-31 |
$-8 |
| 2013-09-30 |
$-15 |
| 2013-06-30 |
$-0 |
| 2013-03-31 |
$-3 |
| 2012-12-31 |
$-4 |
| 2012-09-30 |
$-0 |
| 2012-06-30 |
$0 |
| 2012-03-31 |
$-2 |
| 2011-12-31 |
$1 |
| 2011-09-30 |
$-0 |
| 2011-06-30 |
$-1 |
| 2011-03-31 |
$-1 |
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Consumer Staples |
Tobacco Products |
$0.005B |
$0.032B |
|
22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York.
|
